Cyclosporin in psoriasis: Continuous monotherapy versus intermittent long-term therapy

European Journal of Dermatology

Volumn 9, Issue 3, 1999, Pages 218-223

  Ozawa, Akira ^a   Sugai, Junichi ^a   Ohkido, Muneo ^a   Ohtsuki, Mamitaro ^b   Nakagawa, Hidemi ^b   Kitahara, Hiroto ^c   Tamaki, Kunihiko ^c   Urabe, Kazutaka ^d   Nakayama, Juichiro ^d   Horikoshi, Takasi ^e   Morimoto, Yousuke ^f   Jimbow, Kouichi ^f  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e Omotesando Clinic   (Japan)

^f Sapporo Medical Academy   (Japan)

Author keywords

Cyclosporine A; PASI; Psoriasis; Treatment schedule

Indexed keywords

CREATININE; CYCLOSPORIN A; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EVALUATION; HUMAN; HUMAN TISSUE; HYPERTENSION; LONG TERM CARE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROGNOSIS; PSORIASIS; RELAPSE; REMISSION; TOPICAL DRUG ADMINISTRATION; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PSORIASIS; RECURRENCE; REMISSION INDUCTION; TIME; TREATMENT OUTCOME;

EID: 0032905524     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 1. Mihatsch MJ, Wolff K (Guest editors). Risk/benefit ratio of cyclosporin A (Sandimmun) in psoriasis. Br J Dermatol 1990; 122 (suppl. 36).
2. 2. A consensus report. Cyclosporin A therapy for psoriasis. Br J Dermatol 1990; 122 (suppl. 36): 1-3.
3. 3. Guidelines for cyclosporin therapy in psoriasis. The Research Group for Cyclosporin in Dermatology (Chief: Ishibashi Y, Nakagawa H), Tokyo, Japan, 1992 and 1995 (in Japanese).
4. 4. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Longterm safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623-9.
5. 5. Zachariae H. Longterm use of cyclosporine in dermatology. Arch Dermatol 1996; 132: 692-4.
6. 6. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408.
7. 7. Gollnick HP. Oral retinoids-efficacy and toxicity in psoriasis. Br J Dermatol 1996; 135 (suppl. 49): 6-17.
8. 8. Williams REA. Guidelines for management of patients with psoriasis. BMJ 1991; 303: 829-35.
9. 9. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581-8.
10. 10. Nakayama J, Hori Y, Nakagawa H, Ishibashi Y, Horikoshi T, Ozawa A, Sugai J, Ohkido M. Comparison of two therapeutic regimens, continuous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A. Eur J Dermatol 1996; 6: 341-3.
11. 11. Sugai J, Ozawa A, Kawakubo Y, Iizuka M, Miyahara M, Ohkido M. New method for determining prognosis of patients with psoriasis (E-PAP). J Derm Sci 1998; 16: 165-9.
12. 12. Mihatsch MJ. Histopathology of cyclosporin nephropathy in renal transplants. J Nephrol 4 1990; (suppl. 1): 11-22.
13. 13. Morozumi K. Studies on morphological outcome of cyclosporin-associated arteriopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 1992; 38: 1-8.
14. 14. Powles AV. Renal function after 10 years treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-9.
15. 15. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Arch Dermatol 1995; 131: 791-5.
16. 16. Gottlieb SL, Heftler NS, Gilleaudeau P, Johnson R, Vallat VP, Wolfe J, Gottlieb AB, Krueger JG. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathological study. J Am Acad Dermatol 1995; 33: 637-45.
17. 17. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, Belilovsky C, Brassinne M, Martinet C, Bazex JA, Beylot C, Combemale P, Lambert D, Ostojic A, Denoeux JP, Lauret P, Vaillant L, Weber M, Pamphile R, Dubertret L. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68-74.
18. 18. Menter MA, See JA, Amend WJC, Ellis CN, Krueger GG, Lebwohl M, Morison WL, Prystowsky JH. Proceedings of the psoriasis combination and rotation therapy conference. J Am Acad Dermatol 1996; 34: 315-21.
19. 19. Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 1990; 123: 641-7.
20. 20. Millikan L (Guest editor). Neoral in psoriasis. Int J Dermatol 1997; 36 (suppl. 1).
21. 21. Kragballe K (Guest editor). Vitamin D analogs in dermatology. J Am Acad Dermatol 1997; 37 p.
22. 22. Chandraratna RAS. Tazarotene-first of a new generation of receptor-selective retinoid. Br J Dermatol 1996; 135 (suppl. 49): 18-25.
23. 23. Weinstein GD. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 1996; 135 (suppl. 49): 32-6.